ArticleJournal of ophthalmic & vision research2026
One-year Success Rate of Selective Laser Trabeculoplasty in Pseudoexfoliative Glaucoma: A Prospective Study.
Article in Journal of ophthalmic & vision research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the 1-year effectiveness of selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG). Methods: This prospective, single-arm, non-randomized interventional study involved 40 eyes from 40 patients with PEXG with no history of glaucoma surgery and laser trabeculoplasty. All participants underwent a single session of 360º SLT. Follow-up visits were conducted at 2 hours, 1 day, 1 week, and at 1, 2, 3, 4, 5, 6, and 12 months after the procedure. The intraocular pressure (IOP), the number of anti-glaucoma medications (NOM), and the 1-year success rate were investigated as primary outcome measures; while the incidence of adverse effects was considered the secondary outcome. Treatment success was defined as a Results: The baseline IOP was 22.19 Conclusion: The SLT procedure could significantly reduce IOP in patients with PEXG with minimal adverse effects. The 1-year outcomes were favorable, suggesting that SLT may serve as an effective primary or complementary treatment for PEXG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.